Inventiva S.A.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Inventiva S.A. The largest reported stake is Invus Public Equities, L.P.'s, at 10.6%. 16 filings are on record since July 31, 2025 (Schedule 13G/A, July 31, 2025).

Sofinnova Crossover I SLP also filed stake reports on 1 other company ↓

Sell to companies like Inventiva S.A? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: Andera Partners · Sole voting: 0 · Shared voting: 15,929,476 · Sole dispositive: 0 · Shared dispositive: 15,929,476 · SCHEDULE 13G/A, 2026-10-27
• Filed 2026-05-15 · Holder: Deep Track Capital, LP · Percent: 3.76% · SCHEDULE 13G/A
• Filed 2026-04-01 · Holder: New Enterprise Associates 17, L.P. · Percent: 4.9% · SCHEDULE 13D/A
• Filed 2026-02-17 · Holder: Sofinnova Partners SAS, a French corporation · Percent: 8.6% · SCHEDULE 13G/A
• Filed 2026-02-17 · Holder: Great Point Partners, LLC · Percent: 3.49% · SCHEDULE 13G/A

Inventiva S.A. has 16 Schedule 13D or 13G filings on record since 2025-07-31. 5 holders' latest filing reports 5% or more of ordinary shares, nominal value euro 0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Inventiva S.A. and the warning signs.

See Inventiva S.A.'s free Snapshot Watch Inventiva S.A.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Inventiva S.A. and the records around it.

Inventiva S.A. elsewhere on the record

• Who owns it

Companies that share a holder

• Sofinnova Crossover I SLP also filed stake reports on 1 other company: Abivax S.A. (Jul 2026)
• Andera Partners also filed stake reports on 2 other companies: EVOMMUNE, INC. (Aug 2026), MINERALYS THERAPEUTICS, INC. (Aug 2025)
• New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Korro Bio, Inc. (Mar 2026), SpyGlass Pharma, Inc. (Feb 2026)

Want the whole picture on Inventiva S.A.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Inventiva S.A.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Inventiva S.A. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   16 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Inventiva S.A. by CUSIP 46124U107 and gives its principal executive office as 50 rue de Dijon, Daix (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 237,986,695 ordinary shares outstanding as of September 30, 2026, as reported by the Issuer.Andera Partners, SCHEDULE 13G/A, 2026-10-27

Purpose of Transaction (Item 4)

New Enterprise Associates 17, L.P.

NEA 17 acquired the NEA 17 Shares for investment purposes and GEO acquired the GEO Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17, GEO and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-01; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Inventiva S.A.

Who owns Inventiva S.A.?

On this page, 5 holders' latest ownership filings report 5% or more of Inventiva S.A.: Invus Public Equities, L.P. (10.6%, Schedule 13G/A, filed 2025-07-31), Sofinnova Partners SAS, a French corporation (8.6%, Schedule 13G/A, filed 2026-02-17), Samsara BioCapital, L.P. (7.4%, Schedule 13D/A, filed 2025-11-19), Andera Partners (6.7%, Schedule 13G/A, filed 2026-10-27) and Yiheng Capital Partners, L.P. (5.46%, Schedule 13G/A, filed 2025-11-13).

Who are the largest shareholders of Inventiva S.A.?

By the share each holder's latest filing reports, the largest holders of Inventiva S.A. on this page are Invus Public Equities, L.P. (10.6%), Sofinnova Partners SAS, a French corporation (8.6%) and Samsara BioCapital, L.P. (7.4%).

When did Invus Public Equities, L.P. buy into Inventiva S.A.?

The filings give report dates, not purchase dates. The earliest filing from Invus Public Equities, L.P. on this page is the Schedule 13G/A, filed 2025-07-31, reporting 10.6%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Inventiva S.A.. With no account yet, you sign up free and land on the result.

• Get an alert when Inventiva S.A. is mentioned again
• Find former Inventiva S.A. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes